

Do children with mild asthma need to take inhaled steroids everyday or only as when they need them?

Submission date 15/06/2021	Recruitment status Recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 08/10/2021	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 27/01/2025	Condition category Respiratory	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Asthma is the commonest long-term disease in children in the UK. It causes cough and difficulty breathing. The main treatment for asthma is a preventer inhaler, containing steroids, which prevents irritation of the airways. For many years we have advised children with asthma to use their preventer inhaler every day. However, new guidelines recommend that taking a preventer inhaler every day might not be required in all children. These guidelines are based on results of studies in adults, and some teenagers, with asthma. But, asthma in adults is different from asthma in children and so we need to do the ASYMPTOMATIC trial to provide evidence on whether taking a preventer inhaler only when a child, with mild asthma, has symptoms is as effective as taking it every day.

We want to find out whether there is a difference between the two approaches in terms the chances of having an asthma attack, asthma symptoms, hospital admissions, and overall quality of life.

Who can participate?

The study will involve around 250 GP practices across the UK. Children and young people, with mild asthma, may participate.

What does the study involve?

Participants will be randomly assigned to one of two different approaches to using the preventer inhaler, for 12 months:

1. Taking their inhaler every day
2. Taking their inhaler only when they have symptoms of asthma.

To find out about quality of life and asthma symptoms we will ask participants to complete short questionnaires online at baseline, 4, 8, and 12 months.

What are the possible benefits and risks of participating?

Benefits - At present, the normal practice in preventing asthma attacks is to take steroid inhalers in a "Daily" manner. We know this approach works at reducing asthma attacks.

However, we do not know if taking steroids every day is necessary for all children with mild

asthma. If children could take inhaled steroids only when they needed them, without increasing the risk of asthma attacks, this would have advantages. They would have a smaller amount of steroid over the course of a year and spend less time taking their inhalers.

Risks - There will always be a member of the research team that you can phone if you are concerned about anything or for advice.

Your GP will always be able to change or add to your child's asthma treatment if needed. No additional tests or procedures will be involved over and above normal clinical care, apart from asking you to fill out some short surveys on four occasions over one year.

We have set up an independent team to monitor the results of the study, to check that children are not coming to harm.

Confidentiality will be ensured at all times and you and your child will not be identified in any publication.

Where is the study run from?

Alderhey NHS Trust (UK)

When is the study starting and how long is it expected to run for?

September 2020 to June 2026

Who is funding the study?

National Institute for Health Research (NIHR) (UK).

Who is the main contact?

Prof. Ian Sinha, iansinha@liverpool.ac.uk

Mr Richard Kirk, richard.kirk@alderhey.nhs.uk

Contact information

Type(s)

Scientific

Contact name

Prof Ian Sinha

Contact details

Alder Hey Children's NHS Foundation Trust

Clinical Research Division

Institute in the Park

Eaton Road

Liverpool

United Kingdom

L12 2AP

+44 (0)7920056469

iansinha@liverpool.ac.uk

Type(s)

Public

Contact name

Mr Richard Kirk

Contact details

Alder Hey Children's NHS Foundation Trust
Clinical Research Division
Institute in the Park
Eaton Road
Liverpool
United Kingdom
L12 2AP
+44 (0)1512525803
richard.kirk@alderhey.nhs.uk

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

297649

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

IRAS 297649, CPMS 50134

Study information

Scientific Title

Assessing SYmptom-driven versus Maintenance Preventer Therapy for the Outpatient Management of AsThma In Children (ASYMPTOMATIC): A non-inferiority, pragmatic, randomised controlled trial using routinely collected outcome data

Acronym

ASYMPTOMATIC

Study objectives

This trial aims to examine whether children with mild asthma should use ICS regularly or only when they have symptoms.

The primary objective of this trial is to identify whether in children (aged 6 - 16 years) with mild asthma, symptom-driven use of ICS is non-inferior to daily maintenance ICS on the risk of asthma attacks requiring oral corticosteroid (OCS).

The primary economic objective is to estimate the cost-effectiveness (incremental cost per quality-adjusted life year, QALY gained) of symptom-driven use of ICS.

Secondary objectives are to compare symptom-driven ICS with maintenance ICS with regards to:

1. Asthma control
2. Use of unscheduled health care
3. Hospitalisations
4. HRQoL

5. Treatment failure
6. Mortality
7. Cumulative dose of ICS over the 12 month treatment period

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Interventional randomized controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

GP practice

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet.

Health condition(s) or problem(s) studied

Mild asthma

Interventions

The ASYMPTOMATIC trial is a pragmatic non-inferiority open-label RCT with a 1:1 participant allocation ratio, in general practices across the UK that are registered with the Clinical Practice Research Datalink (CPRD). Data will be obtained from electronic health records (EHR) and approved linked datasets, using routinely collected health information, direct patient report using electronic case report form – (IRSP), and an eCRF for Investigators (IRSP).

We will compare two strategies for using ICS, given over a 52-week treatment period:

Arm 1: Maintenance ICS

IMP: Beclometasone Dipropionate, Fluticasone propionate and Budesonide

Dose: 200 mcg/24 hours, Budesonide equivalent, for 6 - 11-year-olds, 400 mcg/24hours, Budesonide equivalent, for 12 - 16-year-olds daily. (inhaled)

Arm 2: Symptom driven ICS

IMP: Beclometasone Dipropionate, Fluticasone propionate and Budesonide

Dose: 200 mcg/24 hours, Budesonide equivalent, for 6 - 11-year-olds, 400 mcg/24hours, Budesonide equivalent, for 12 - 16-year-olds, on days where short acting beta agonist is used.

The primary outcome is the occurrence of at least one asthma attack requiring treatment with OCS over the 12 month treatment/follow up period. Secondary outcomes will be asthma control, HRQoL, treatment failure, unscheduled healthcare utilisation, cumulative dose of ICS in the last

12 months, mortality and hospitalisations. We will also undertake a cost-effectiveness analysis of the two approaches.

The ICS (beclomethasone, fluticasone, or budesonide 200 mcg/24 hours for 6-11 year olds, 400 mcg/24hours for 12 - 16-year-olds) will be chosen by the GP, in line with their local processes, prior to randomisation and their choice of inhaler recorded in the randomisation system. ICS will be administered using a metered dose inhaler (MDI) and, if required, spacer device. A dry powder inhaler may be used for children aged 12 years and over.

Participants will be randomised to Arm 1 or Arm 2 and will receive treatment in line with the allocated arm for 12 months from randomisation. Participants will be followed up, at intervals over the 12 month treatment period, using the EHR and patient-reported outcome data.

We aim to minimise participant attrition by using routine EHR data for follow-up outcomes without the need for additional trial-specific visits.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Beclometasone dipropionate, fluticasone propionate, budesonide

Primary outcome measure

1. Number of asthma attacks requiring treatment with OCS in the 12-months after randomisation. Information on this outcome will be obtained from prescription records and through linkage with Hospital Episode Statistic (HES) data.
 2. Cost per QALY gained (ICER) over the 12 month treatment/follow up period measured using:
 - 2.1. CHU-9D questionnaire responses at baseline, 4, 8- and 12-months
 - 2.3. Resource use from HES and CPRD data at the end of the trial
 - 2.4. For utilities: application of UK tariff scores
 - 2.5. For QALYs: area under the utility-time curve
 - 2.6. For costs: sum-product of all measured items of resource use and their respective NHS unit costs
- ICER calculated as the difference in total costs between intervention groups, divided by the difference in QALYs.

Secondary outcome measures

At 4, 8 and 12 months after randomisation

1. Asthma control measured using Asthma Control Test (ACT)
2. Participant adherence to the intervention (adherence questionnaire)
3. Health utility (CHU9D tool)
4. Cumulative dose of ICS over the 12 month treatment period (estimated from the number of ICS inhalers prescribed, as indicated from prescription records)
5. Treatment failure (i.e. when LABA or LTRA additional preventer therapies were prescribed, as determined from prescription records)
6. Hospitalisation and mortality will be identified from linked HES data
7. Serious Adverse Events (SAEs). SAEs will be reviewed by the CI and Suspected Unexpected Serious Adverse Reactions (SUSARs) reported accordingly by GPs

Overall study start date

30/09/2020

Completion date

01/06/2026

Eligibility

Key inclusion criteria

1. Aged 6 - 15 years inclusive
2. Mild asthma, including children with a new diagnosis.
3. At least one relevant (for asthma) prescription of short acting beta agonists (SABA) or inhaled corticosteroids (ICS) in the last 12 months (including new diagnoses)
4. Written and informed consent and assent from the participant's legal representative and participant respectively (for participants under 16 years of age) and agreement of the participant to comply with the requirements of the trial
5. Ability of the parent, and young person where appropriate, to complete patient reported outcomes in English

Participant type(s)

Patient

Age group

Child

Lower age limit

6 Years

Upper age limit

15 Years

Sex

Both

Target number of participants

1,854

Key exclusion criteria

1. Hospitalised for asthma in the last 12 months (this does not include children who have attended the ED but not been admitted)
2. Three or more asthma attacks treated with oral corticosteroids in the last 12 months
3. Significant respiratory comorbidity including cystic fibrosis, immunodeficiency or interstitial lung disease
4. Prescribed, or taking, any of the following at the time of randomisation: montelukast, long acting beta-agonist whether in combination with ICS or as a separate inhaler, azithromycin (given prophylactically). Patients who have previously received these treatments but who are no longer receiving them at the time of randomisation i.e. treatment has been stepped down, are not excluded.

Date of first enrolment

01/07/2021

Date of final enrolment

31/12/2025

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

NIHR CRN North East and North Cumbria

Regent Point

Regent Farm Road

Gosforth

Newcastle Upon Tyne

United Kingdom

NE3 3HD

Study participating centre

NIHR Clinical Research Network, North West Coast

iC1 Liverpool Science Park

131 Mount Pleasant

Liverpool

United Kingdom

L3 5TF

Study participating centre

NIHR CRN: Yorkshire and Humber

8 Beech Hill Road

Sheffield

United Kingdom

S10 2SB

Study participating centre

NIHR CRN: Greater Manchester

2nd Floor, Citylabs

Nelson Street

Manchester

United Kingdom

M13 9NQ

Study participating centre
NIHR CRN: East Midlands
Knighton Street Outpatients
1st Floor
Leicester
United Kingdom
LE1 5WW

Study participating centre
NIHR CRN: West Midlands
James House,
Newport Road
Albrighton
Wolverhampton
United Kingdom
WV7 3FA

Study participating centre
NIHR CRN: West of England
Whitefriars
Lewins Mead
Bristol
United Kingdom
BS1 2NT

Study participating centre
NIHR CRN: Thames Valley and South Midlands
Headley Way
Headington
Oxford
United Kingdom
OX3 9DU

Study participating centre
NIHR CRN: Eastern
Floor 4
Rouen Road
Norwich
United Kingdom
NR1 1QQ

Study participating centre
NIHR CRN: Kent, Surrey and Sussex
Bevendean House
Room BE205
University of Brighton
Falmer
Brighton
United Kingdom
BN1 9PH

Sponsor information

Organisation
Alder Hey Children's NHS Foundation Trust

Sponsor details
Clinical Research Division
Institute in the Park
Eaton Road
Liverpool
England
United Kingdom
L12 2AP
+44 (0)151 252 5803
research@alderhey.nhs.uk

Sponsor type
Hospital/treatment centre

Website
<https://alderhey.nhs.uk/>

ROR
<https://ror.org/00p18zw56>

Funder(s)

Funder type
Government

Funder Name
National Institute for Health Research

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal. Participants will be informed that a copy of the study results will be made available on the study website at the end of the trial. We will also circulate a summary of results to relevant patient organisations for dissemination.

Intention to publish date

01/07/2026

Individual participant data (IPD) sharing plan

All data generated or analysed during this study will be included in the subsequent results publication.

IPD sharing plan summary

Other